Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Oklahoma attorney general to appeal judge's opioid ruling

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/21/2019 | 01:23pm EST

OKLAHOMA CITYOklahoma Attorney General Mike Hunter says he plans to appeal a judge’s order directing consumer products giant Johnson & Johnson to pay the state $465 million to help address the state’s opioid crisis.

Hunter said Thursday the judge’s final order only covers one year of the state’s proposed abatement plan and that the actual costs to clean up the damage from the opioid crisis are much higher.

Attorneys for the company also say they plan to appeal.

Johnson & Johnson had asked the judge to consider reducing the final award based on pre-trial settlements totalling $355 million the state reached with other defendants in the case.

Cleveland County Judge Thad Balkman initially ordered the company to pay $572 million, but later reduced that amount after acknowledging a miscalculation.

© 2019 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/11JOHNSON & JOHNSON : Janssen Pharmaceutical - DARZALEX Regimen Shows Significant ..
AQ
12/10JOHNSON & JOHNSON : appeals Oklahoma judge's opioid ruling
AQ
12/10JOHNSON & JOHNSON : to Host Investor Conference Call on Fourth-Quarter Results
PR
12/10JOHNSON & JOHNSON : Vaccine Regimen from Janssen and Bavarian Nordic to Support ..
AQ
12/10JOHNSON & JOHNSON : Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-..
AQ
12/10JOHNSON & JOHNSON : Janssen Pharmaceutical - DARZALEX Shows Overall Survival Ben..
AQ
12/10AMGEN : Phase 3 Study Combining Kyprolis, Darzalex Met Primary Endpoint
DJ
12/09WISETECH GLOBAL LTD (ASX : WTC) Acquires South Korean Solutions Provider, Ready ..
AQ
12/09JOHNSON & JOHNSON : Janssen to Acquire Investigational Bermekimab from XBiotech
PU
12/09XBiotech Shares Jump After Selling Bermekimab to Janssen
DJ
More news
Financials (USD)
Sales 2019 82 175 M
EBIT 2019 25 638 M
Net income 2019 17 334 M
Debt 2019 6 823 M
Yield 2019 2,66%
P/E ratio 2019 21,6x
P/E ratio 2020 19,1x
EV / Sales2019 4,61x
EV / Sales2020 4,33x
Capitalization 372 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,90  $
Last Close Price 141,38  $
Spread / Highest target 22,4%
Spread / Average Target 6,03%
Spread / Lowest Target -8,76%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.52%372 094
ROCHE HOLDING AG24.22%261 287
MERCK AND COMPANY16.73%227 076
PFIZER-12.19%212 123
NOVARTIS22.85%210 097
BRISTOL-MYERS SQUIBB COMPANY23.01%149 606